|
Feb 19
|
Biotech Stock Roundup: MRNA's Q4 Results, GILD's Update & Other News
|
|
Feb 19
|
Solid Biosciences’ stock soars on early success in DMD gene therapy trial
|
|
Feb 18
|
Solid Biosciences Shares Up After Positive Results From Duchenne Drug Study, Prices $200 Million Offering
|
|
Feb 18
|
Solid Biosciences Announces Pricing of Underwritten Offering
|
|
Feb 18
|
Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003
|
|
Feb 18
|
Solid says early data suggest ‘differentiated’ Duchenne gene therapy
|
|
Sep 23
|
Solid Biosciences to Participate at Chardan’s 8th Annual Genetic Medicines Conference
|
|
Aug 13
|
Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates
|
|
Jul 1
|
Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
|
Jul 1
|
Solid Biosciences Joins the Russell 3000® Index
|
|
Jun 2
|
We Think Solid Biosciences (NASDAQ:SLDB) Can Afford To Drive Business Growth
|
|
May 15
|
Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results
|
|
May 7
|
Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting
|
|
Apr 3
|
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Apr 2
|
Solid Biosciences (SLDB) Falls Despite FDA Rare Tag for DMD Drug
|
|
Apr 1
|
Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
|
|
Mar 28
|
How Sleeper Biotech Solid Biosciences, With A 687% Gain, Is Making A Comeback
|
|
Mar 27
|
Solid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy Symposium
|
|
Mar 13
|
Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results
|
|
Mar 7
|
Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD
|